Please provide your email address to receive an email when new articles are posted on . The Hadassah Self-Visual Acuity Screener demonstrated high reliability, accuracy and alignment with standard ...
Please provide your email address to receive an email when new articles are posted on . Mitch Ibach, OD, of Vance Thompson Vision, and colleagues conducted a phase 2, multicenter, randomized, ...
The U.S. Food and Drug Administration has approved Yuvezzi (carbachol and brimonidine tartrate) ophthalmic solution 2.75%/0.1 ...
The Companies plan to file an application with the FDA in the second half of 2025. Topline data were announced from a phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for the ...
Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...
Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...
Up to 19% of prevalent dementia cases may be attributable to impaired vision, a cross-sectional analysis suggested. Contrast sensitivity impairment showed the strongest relationship, followed by near ...
New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment intensity for underlying nAMD remained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results